COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NCL News Archive

Monday, July 10, 2017

Inaugural FNLCR Technology Showcase Draws Hundreds

More than 200 science and business professionals from across the region attended the Frederick National Laboratory for Cancer Research’s (FNLCR) Inaugural Technology Showcase event. The program highlighted technologies developed by NCI and FNLCR investigators available for license or other collaborative development. In addition, Frederick city and county officials highlighted partnership... View Post

Wednesday, May 3, 2017

Nanomedicine Award 2017

The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium ENATRANS have launched the third edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2017.

The goal of the Award is to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering unmet... View Post

Wednesday, May 3, 2017

New Innovative Research in Cancer Nanotechnology (IRCN) Funding Opportunity Announcement (R01)

NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative, PAR-17-240. All IRCN awards made through this announcement are R01 grants and will be part of the Alliance for Nanotechnology in Cancer network. Due dates are twice per year, with the announcement remaining open until... View Post

Tuesday, April 4, 2017

2017 FNLCR Technology Showcase

The Frederick National Laboratory for Cancer Research (FNLCR) will be hosting a half-day event that will showcase technologies being developed at the National Cancer Institute (NCI) and FNLCR. The event aims to introduce the Frederick community to the regional technology development stakeholders, highlight available resources, as well as to encourage startup company formation, technology... View Post

Friday, March 3, 2017

Equivalence of Complex Drug Products: Scientific and Regulatory Challenges

Missed the NYAS meeting on “Equivalence of Complex Drug Products: Scientific and Regulatory Challenges”? The academy has just published an e-briefing from the meeting. Here you will be able to find notes from the meeting, as well as videos of select presentations. You can also find links to related publications and websites.

The meeting was co-organized by the Non Biological... View Post

Thursday, February 2, 2017

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.

The first issue of ACS Nano for 2017 features an article on the “Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.” The article, co-authored by NCL’s Senior Immunologist, Marina Dobrovolskaia, along with several other well-known names in the field, summarizes the topics of discussion from a recent meeting on the subject. The two-day workshop was held... View Post

Tuesday, December 6, 2016

Nature Reviews Materials

NCL’s Director, Scott McNeil, recently published a Correspondence article in Nature Reviews Materials. “Evaluation of nanomedicines: Stick to the basics”, was written in response to another recent Nature Reviews Materials article, Wilhelm, et al, Nature Reviews Materials, 2016, 1, 16014. The Wilhelm, et al. article provides a retrospective analysis of nanoparticle drug... View Post

Tuesday, December 6, 2016

Join our LinkedIn group on Nanomedicine Preclinical Development

NCL has created a focus group on LinkedIn, designed to connect researchers within the nanotech field. The aim of the group will be to discuss the latest news, trends, and issues of Nanomedicine Preclinical Development.

Join here:

Tuesday, December 6, 2016

Nature Reviews publication

The NCL has recently published a review article entitled “Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer” in Nature Reviews Clinical Oncology. The review highlights current nanomedicine strategies being used to target one of the most devastating cancers.

Find the Advance Online publication here: View Post

Monday, November 28, 2016

Nanomedicine Pharmacokinetics Publication

NCL’s Sr. Principal Scientist in Pharmacology & Toxicology, Dr. Stephan Stern, has spearheaded several important publications on the complexity of nanomedicine pharmacokinetics and the importance of measuring all drug fractions—nanomedicine encapuslated, protein-bound, and free unbound drug—when evaluating nanomedicine PK. The most recent of these publications is entitled “When Is It... View Post